Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › LA › New Orleans › NPI 1821098286
Hospital

Touro Infirmary

Touro Infirmary was paid $20.55M by Medicaid between Jan 2018 and Dec 2024, across 175 billing codes. Its largest line is 99285, emergency room visit (most serious) — 21% of everything it billed.

33Billing provider infoTOURO INFIRMARY
NEW ORLEANS, LA 70115
33aNPI1821098286assigned 07/28/2005
28Total paid$20.55M
24GClaims531,843
24DCodes billed175
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other General Acute Care Hospital providers in Louisiana

Rank by total paid#22 of 96
Median peer was paid$5.17M
This provider vs. median4.0×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$200K$400K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
201855,988$2.04M
201956,841$2.22M
202045,052$1.85M
202191,391$3.68M
2022100,803$3.88M
2023106,751$3.91M
2024incomplete75,017$2.97M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
99285 Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life 21% 25,227 22,632 $4.30M
99284 Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity 19% 30,031 27,317 $3.86M
99213 Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity 13% 79,395 59,542 $2.61M
99283 Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity 6.8% 16,430 14,958 $1.39M
99214 Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 6.6% 28,512 24,484 $1.36M
76816 Ultrasound, pregnant uterus, real time with image documentation, follow-up 3.5% 8,704 6,665 $728K
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report 3.0% 21,501 18,766 $611K
76811 Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed 2.5% 7,037 4,860 $521K
96374 Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance 2.2% 16,618 13,898 $458K
43239 Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple 1.9% 1,364 1,193 $400K
76819 Fetal biophysical profile; without non-stress testing 1.9% 5,271 3,377 $391K
11042 Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm 1.8% 1,984 1,004 $380K
163 more codes
59025 Fetal non-stress test 1.3% 1,729 $274K
71045 Radiologic examination, chest; single view 1.1% 9,369 $232K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe 1.1% 6,106 $221K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular <1% 9,913 $188K
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward <1% 6,524 $174K
85025 Blood count; complete (CBC), automated, and automated differential WBC count <1% 36,487 $168K
96375 Therapeutic injection; each additional sequential IV push <1% 6,027 $155K
80053 Comprehensive metabolic panel <1% 23,019 $137K
76817 Ultrasound, pregnant uterus, real time with image documentation, transvaginal <1% 1,565 $134K
81025 <1% 21,308 $129K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 2,136 $115K
J7307 Etonogestrel (contraceptive) implant system, including implant and supplies <1% 157 $106K
96413 Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance <1% 1,701 $101K
99215 Doctor's office visit, returning patient (complex) <1% 2,176 $92K
96361 Intravenous infusion, hydration; each additional hour <1% 6,329 $88K
0241U Neonatal screening for hereditary disorders, genomic sequence analysis panel <1% 860 $85K
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets <1% 1,184 $83K
99211 Office or other outpatient visit for the evaluation and management of an established patient, minimal severity <1% 3,000 $79K
80047 <1% 11,506 $77K
36415 Collection of venous blood by venipuncture <1% 45,259 $74K
84484 <1% 12,053 $71K
G0121 Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk <1% 280 $54K
0002A <1% 1,347 $43K
0001A <1% 1,368 $41K
76801 <1% 544 $41K
71046 Radiologic examination, chest; 2 views <1% 685 $35K
81001 <1% 15,071 $33K
J7298 Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg <1% 57 $33K
74176 Computed tomography, abdomen and pelvis; without contrast material <1% 101 $28K
76815 Ultrasound, pregnant uterus, real time with image documentation, limited <1% 1,160 $27K
76818 <1% 570 $26K
80076 <1% 5,066 $24K
83880 <1% 1,410 $23K
70450 Computed tomography, head or brain; without contrast material <1% 168 $21K
87426 Infectious agent antigen detection, SARS-CoV-2 (COVID-19) <1% 585 $18K
97110 Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion <1% 761 $18K
93306 Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete <1% 122 $18K
76805 Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation <1% 185 $18K
83690 <1% 3,051 $13K
87086 Culture, bacterial; quantitative colony count, urine <1% 2,239 $12K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay <1% 259 $12K
76856 Ultrasound, pelvic (nonobstetric), real time with image documentation; complete <1% 126 $12K
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour <1% 177 $10K
81003 <1% 5,787 $10K
45380 Colonoscopy, flexible; with biopsy, single or multiple <1% 47 $9K
0004A <1% 260 $9K
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe <1% 297 $8K
96360 Intravenous infusion, hydration; initial, 31 minutes to 1 hour <1% 158 $8K
51705 <1% 143 $8K
76820 <1% 96 $7K
85027 <1% 2,075 $7K
G0378 Hospital observation service, per hour <1% 92 $7K
J7030 Infusion, normal saline solution , 1000 cc <1% 2,120 $7K
45378 Colonoscopy, flexible; diagnostic, including collection of specimen(s) <1% 27 $7K
77067 Screening mammography, bilateral, including computer-aided detection <1% 308 $6K
99282 Emergency department visit for the evaluation and management, low to moderate severity <1% 121 $6K
90715 <1% 371 $6K
82550 <1% 1,928 $6K
83735 <1% 1,759 $6K
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml <1% 57 $4K
19301 <1% 14 $4K
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 1,092 $3K
77063 Screening digital breast tomosynthesis, bilateral <1% 231 $3K
82962 <1% 1,418 $3K
73562 <1% 59 $3K
80048 Basic metabolic panel (calcium, ionized) <1% 524 $3K
83615 <1% 801 $2K
73120 <1% 47 $2K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe <1% 74 $2K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe <1% 74 $2K
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine <1% 1,325 $2K
99395 Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years <1% 451 $2K
90674 <1% 333 $2K
94060 <1% 27 $2K
76641 <1% 31 $2K
93296 <1% 531 $2K
76705 Ultrasound, abdominal, real time with image documentation; limited <1% 42 $2K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 124 $2K
J2405 Injection, ondansetron hydrochloride, per 1 mg <1% 1,379 $1K
J1642 Injection, heparin sodium, (heparin lock flush), per 10 units <1% 4,921 $1K
85730 <1% 493 $1K
J1100 Injection, dexamethasone sodium phosphate, 1 mg <1% 676 $1K
0003A <1% 41 $1K
J1050 Injection, medroxyprogesterone acetate, 1 mg <1% 2,329 $1K
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc <1% 28 $1K
94729 <1% 27 $1K
85014 <1% 857 $1K
85610 <1% 534 $1K
97161 <1% 26 $968.24
87070 <1% 119 $934.18
82248 <1% 330 $862.32
G2066 Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results <1% 227 $800.22
83970 <1% 29 $743.04
94726 <1% 14 $739.20
83605 <1% 140 $733.62
74022 <1% 14 $729.68
87210 <1% 166 $726.44
73610 <1% 14 $718.70
96523 <1% 63 $702.97
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 33 $667.00
80069 <1% 97 $581.56
86710 <1% 63 $526.37
82947 <1% 103 $524.50
73630 <1% 14 $474.72
Q0162 Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen <1% 17 $434.79
90686 <1% 48 $429.19
83036 Hemoglobin; glycosylated (A1C) <1% 56 $398.13
80061 Lipid panel <1% 38 $374.92
84443 Thyroid stimulating hormone (TSH) <1% 29 $372.34
82728 <1% 44 $368.01
84702 <1% 34 $346.15
82570 <1% 62 $336.70
73030 <1% 13 $316.84
97602 <1% 37 $300.03
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed <1% 17 $296.00
82553 <1% 50 $284.76
J2270 Injection, morphine sulfate, up to 10 mg <1% 234 $278.61
84153 <1% 36 $239.07
87400 <1% 46 $237.07
82043 <1% 62 $236.98
83550 <1% 43 $235.98
93298 <1% 106 $228.79
83540 <1% 44 $171.18
84100 <1% 58 $161.16
87430 <1% 14 $159.50
80348 <1% 12 $127.74
J0696 Injection, ceftriaxone sodium, per 250 mg <1% 13 $122.51
84156 <1% 44 $106.43
J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg <1% 20 $91.41
81002 <1% 29 $85.50
J0173 Injection, epinephrine (belcher), not therapeutically equivalent to j0171, 0.1 mg <1% 49 $85.04
87081 <1% 14 $80.96
91300 <1% 3,356 $73.39
99396 Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years <1% 18 $72.84
J2930 Injection, methylprednisolone sodium succinate, up to 125 mg <1% 13 $66.01
J2704 Injection, propofol, 10 mg <1% 1,189 $58.65
85018 <1% 24 $51.71
A6197 Alginate or other fiber gelling dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., each dressing <1% 22 $51.20
90661 <1% 21 $50.85
94799 <1% 315 $31.80
99152 <1% 14 $31.35
J3010 Injection, fentanyl citrate, 0.1 mg <1% 167 $24.44
J2272 Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg <1% 17 $23.20
J2250 Injection, midazolam hydrochloride, per 1 mg <1% 206 $15.73
J7050 Infusion, normal saline solution, 250 cc <1% 67 $15.68
J7512 Prednisone, immediate release or delayed release, oral, 1 mg <1% 21 $10.56
J2060 Injection, lorazepam, 2 mg <1% 15 $8.99
90472 Immunization administration, each additional vaccine (list separately) <1% 17 $3.32
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit) <1% 26 $3.11
C9803 Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source 0% 1,457 $0.00
99001 0% 109 $0.00
J1596 Injection, glycopyrrolate, 0.1 mg 0% 110 $0.00
V2787 Astigmatism correcting function of intraocular lens 0% 39 $0.00
G1004 Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program 0% 38 $0.00
76098 0% 15 $0.00
J0744 Injection, ciprofloxacin for intravenous infusion, 200 mg 0% 16 $0.00
93798 0% 77 $0.00
G0463 Hospital outpatient clinic visit for assessment and management of a patient 0% 1,455 $0.00
J0690 Injection, cefazolin sodium, 500 mg 0% 76 $0.00
J2003 Injection, lidocaine hydrochloride, 1 mg 0% 194 $0.00
C9290 Injection, bupivacaine liposome, 1 mg 0% 58 $0.00
V2632 Posterior chamber intraocular lens 0% 15 $0.00
91305 0% 12 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialHAGGARD, SUZANNE (CHIEF FINANCIAL OFFICER VP)
Same official

Other billing entities under HAGGARD, SUZANNE

Full network →
ProviderLocationPaid
LCMC Health Clinical Services, LLCNew Orleans, LA$2.92M

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.